- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06750146
Hot AXIOS™ för gallgångsdränering vid malign stenos (RAINBOW)
Fransk prospektiv studie om dränering av gallvägar vägledd av endoskopiskt ultraljud hos patienter med malign gallstenos (RAINBOW)
The study is designed to highlight the effectiveness of the Hot AXIOS™ stent when used in accordance with standard medical practice on the evolution of the quality of life of patients with malignant biliary stenosis requiring drainage of the bile ducts after failure of ERCP, in the two months after stent placement.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The study will evaluate the quality of life in patients with malignant biliary obstruction after the placement of a lumen-apposing metal stent via endoscopic ultrasound, with an emphasis on the improvement of quality of life measured as a reduction in jaundice. Improvement in jaundice is a direct indicator of effective bile drainage and is expected to correlate with an enhancement in overall quality of life. Quality of life will be measured by means of subject response to the EORTC QLQ-BIL21, a component of the European Organization for Research and Treatment of Cancer (EORTC) designed specifically to assess the quality of life in patients with biliary tract cancer. The QLQ-BIL21 consists of 21 questions which aim to evaluate specific symptoms and issues relevant to patients with biliary tract cancer, such as jaundice, pain, digestive problems and the psychosocial impact of the disease.
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
-
Besançon, Frankrike, 25030
- CHU de Besançon
-
Cornebarrieu, Frankrike, 31700
- Clinique des Cedres, Ramsay Sante
-
Limoges, Frankrike, 87042
- CHU Limoges
-
Lyon, Frankrike, 69008
- Hopital Prive Jean Mermoz
-
Nantes, Frankrike, 44300
- Clinique Jules Verne
-
Nice, Frankrike, 06202
- CHU Nice
-
Paris, Frankrike, 75012
- Hopital Saint Antoine
-
Paris, Frankrike, 75908
- Hopital Europeen Georges-Pompidou
-
Paris, Frankrike, 75014
- Hopital Paris Saint-Joseph
-
Poitiers, Frankrike, 86021
- CHU de Poitiers
-
Reims, Frankrike, 51092
- CHU Reims
-
Rennes, Frankrike, 35033
- CHRU Hopital Pontchaillou
-
Rouen, Frankrike, 76000
- Clinique Saint-Hilaire
-
Saint-Herblain, Frankrike, 44800
- Santé Atlantique
-
Strasbourg, Frankrike, 67091
- CHU de Strasbourg
-
Toulouse, Frankrike, 31059
- CHU Rangueil
-
Vandœuvre-lès-Nancy, Frankrike, 54500
- CHRU de Nancy
-
Vichy, Frankrike, 03200
- Centre Hospitalier de Vichy
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Patients 18 years or older
- Willing and able to comply with study procedures and provide written informed consent
- Patients with failed ERCP for treatment of suspected malignant biliary obstruction
- Patients for whom an indication for Hot AXIOS™ stent placement has been determined
Exclusion Criteria:
- Women who are pregnant, nursing or planning to become pregnant during the study
- Patients with immediately resectable tumor or resectable during the two months of the study
- Patients for whom the placement of a double pigtail prosthesis is planned by the investigator during the index procedure
- Current participation in another investigation drug or device study that could interfere with the endpoints of this study
- Persons under guardianship or curatorship
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Hot AXIOS™ Recipients
The Hot AXIOS™ Stent is a flexible, fully covered self-expanding metal stent that is preloaded within the Electrocautery Enhanced Delivery System. Patients who meet all eligibility criteria will receive the Hot AXIOS™stent and their quality of life will be measured at baseline, two weeks after stent placement and two months after stent placement by the jaundice dimension of the EORTC QLQ-BIL21 questionnaire. A patient is considered enrolled after signing the study-specific Informed Consent Form (ICF). Patients who sign the ICF but subsequently do not meet one or more of the selection criteria will be considered screen failures and excluded from the study. |
The Hot AXIOS™ Stent and Electrocautery Enhanced Delivery System is commercially available and can be used to bridge two lumens or organs to create an internal drain, so as to drain the bile ducts in case of failure of ERCP.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Quality of Life Measurement - Jaundice Dimension
Tidsram: 2 months (± 15 days)
|
The primary outcome is the difference between the measurement taken at 2 months of follow-up (± 15 days) and the baseline measurement of quality of life assessed by the jaundice dimension of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-BIL21). The QLQ-BIL21 consists of 21 questions to which respondents rate their experience with various symptoms or problems on a scale from 1 (Not at All) to 4 (Very Much); the jaundice dimension consists of three of those questions. A lower score correlates to fewer symptoms or problems. |
2 months (± 15 days)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Quality of Life Measurement - Non-Jaundice Dimension
Tidsram: 2 months (± 15 days)
|
The absolute difference between the measurement taken at 2 months of follow-up (± 15 days) and the baseline measurement of quality of life assessed by the non-jaundice dimension of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-BIL21). The QLQ-BIL21 consists of 21 questions to which respondents rate their experience with various symptoms or problems on a scale from 1 (Not at All) to 4 (Very Much); the non-jaundice dimension consists of 18 of those questions. A lower score correlates to fewer symptoms or problems. |
2 months (± 15 days)
|
|
Quality of Life Measurement - Global Score
Tidsram: 2 months (± 15 days)
|
The absolute difference between the measurement taken at 2 months of follow-up (± 15 days) and the baseline measurement of quality of life assessed by the global score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-BIL21). The QLQ-BIL21 consists of 21 questions to which respondents rate their experience with various symptoms or problems on a scale from 1 (Not at All) to 4 (Very Much). A lower score correlates to fewer symptoms or problems. |
2 months (± 15 days)
|
|
Reduction in Bilirubin (Clinical Success)
Tidsram: 2 weeks (+ 7 days) and 2 months (± 15 days)
|
Clinical success is defined as a reduction in bilirubin > 50% at each follow-up compared to baseline. |
2 weeks (+ 7 days) and 2 months (± 15 days)
|
|
Rate of Resolution of Clinical Symptoms
Tidsram: 2 months (± 15 days)
|
Resolution of GOO-related clinical symptoms such as jaundice, nausea/vomiting, fever/chills, weight loss and abdominal pain following implant of Hot AXIOS™ at 2 months of follow-up |
2 months (± 15 days)
|
|
Rate of Reintervention
Tidsram: 2 months (± 15 days)
|
Reintervention is defined as endoscopic, radiological or surgical intervention for the management of recurrent biliary obstruction due to stent dysfunction (e.g., obstruction or migration) at 2 months of follow-up. This criterion will be measured within the population for whom the placement of the Hot AXIOS™ stent was a technical success. |
2 months (± 15 days)
|
|
Chemotherapy Status
Tidsram: 2 months (± 15 days)
|
Number of days after study stent implantation to start or continuation of chemotherapy (if applicable). |
2 months (± 15 days)
|
|
Overall Survival
Tidsram: 2 months (± 15 days)
|
Time from the placement of the Hot AXIOS™ to the date of death from any cause or to the end of follow-up (end of study participation or lost to follow-up) to assess summary measure overall survival. |
2 months (± 15 days)
|
|
Progression-Free Survival
Tidsram: 2 months (± 15 days)
|
Time from the placement of the Hot AXIOS™ to the earliest date of either disease progression or death from any cause or to the end of follow-up (end of study participation or lost to follow-up) to assess summary measure progression-free survival. |
2 months (± 15 days)
|
|
Number of Days Alive after Hospital Discharge
Tidsram: 2 months (± 15 days)
|
Number of days alive after hospital discharge within 2 months after the placement of the Hot AXIOS™. |
2 months (± 15 days)
|
|
Rate of Technical Success
Tidsram: 2 months (± 15 days)
|
Technical success is defined as the successful placement of the Hot AXIOS™ stent during study procedure. |
2 months (± 15 days)
|
|
Serious Adverse Events
Tidsram: 2 months (± 15 days)
|
Serious adverse events related to the study procedure and/or the Hot AXIOS™ stent. |
2 months (± 15 days)
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Jean-Baptiste Chevaux, Central Hospital, Nancy, France
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- E7209
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .